

<b>Notice of References Cited</b>	Application/Control No. 09/259,658	Applicant(s)/Patent Under Reexamination COLYER ET AL.	
	Examiner Ginny Portner	Art Unit 1645	Page 1 of 2

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-2003/0104504	06-2003	Colyer et al.	435/7.92
	B	US-5,932,421	08-1999	Ginsberg et al.	435/6
	C	US-5,185,248	02-1993	Barbacid et al.	435/15
	D	US-5,736,337	04-1998	Avruch et al.	435/7.1
	E	US-6,103,692	08-2000	Avruch et al.	514/12
*	F	US-5,582,995	12-1996	Avruch et al.	435/7.1
	G	US-5,637,463	06-1997	Dalton et al.	435/6
	H	US-5,565,352	10-1996	Hochstrasser et al.	435/255.1
	I	US-6,808,874	10-2004	Griffiths, Gary	435/4
	J	US-6,569,833	05-2003	Fahraeus et al.	514/13
	K	US-6,613,878	09-2003	Cox et al.	530/328
	L	US-5,637,463	06-1997	Dalton et al.	435/6
	M	US-6,410,255	06-2002	Pollok et al.	435/23

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	90/14431	11-1990	wo	Cronan	c12p 21/00
	O					
	P					
	Q					
	R					
	S					
	T					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Manne, V et al, Drug Development REsearch, Vol. 34, 1995, pages 121-137, Ras farnesylation as a target for novel antitumor agents:Potent and selective farnexyl diphosphate analog inhibitors of farnesyltransferase.
	V	SpA scintillation proximity assay, Cytostar-T scintillating microplate, November 1997, Issue No. 35, Proximity News, Scintillation Proximity Assay (SPA) Bibliography, Amersham Life Science,pages 1-8, listing of references for protein-protein interactions.
	W	Leftheris, K et al, J. Med. Chem, 1996, Vol. 39, pages 224-236, Developmnet of Highly Potent Inhibitors of Ras Farnesyltransferase Processing and in vivo activity.
	X	Kohl, Nancy E., Farnesyltransferase Inhibitors, Preclinical Development, pages 91-102, Annals New York Academy of Sciences, 1999, Vol. 886.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 09/259,658	Applicant(s)/Patent Under Reexamination COLYER ET AL.	
	Examiner Ginny Portner	Art Unit 1645	Page 2 of 2

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,410,255	06-2002	Pollok et al.	435/23
	B	US-6,810,362	10-2004	Adachi et al.	702/187
	C	US-6,117,641	09-2000	Berlin et al.	435/7.1
	D	US-6,261,793	07-2001	Whyte et al.	435/15
	E	US-5,990,277	11-1999	Levitzki et al.	530/330
	F	US-5,578,477	11-1996	Tamanoi, Fuyuhiko	435/193
	G	US-5,789,541	08-1998	Rando, Robert R.	530/326
*	H	US-5,185,248	02-1993	Barbacid et al.	435/15
	I	US-6,037,136	03-2000	Beach et al.	435/7.4
	J	US-6,808,874	10-2004	Griffiths, Gary	435/4
	K	US-			
	L	US-			
	M	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Omer, CA et al, Ca1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents, TIPS, Nov. 1997, Vol. 18, pages 437-445.
	V	Qian, Y et al, Farnesyltransferase as a target for anticancer drug design, Biopoly, Vol. 43, pages 25-41, 1997
	W	Lebowitz, Peter F. et al, Molecular and Cellular Biology, Dec. 1995, Vol. 15(12), pages 6613-6622, Evidence that Farnesyltransferase inhibitors suppress RAs transformation by interfering with Rho activity.
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.